Souhaitez-vous accéder aux communiqués récents ?

Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy

Avance Clinical Appoints Inaugural Chief Commercial Officer, Reinforcing Global Growth Strategy

Approval is based on unprecedented Phase 3 data showing statistically significant improvements in progression-free and overall survival versus standard of care regimens1This immunotherapy doublet...

York, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- WellSpan Health and Johns Hopkins Medicine today announced the next phase of an oncology collaboration that will further strengthen access to advanced...

NeOnc’s (NASDAQ: NTHI) CEO purchased more shares on the open market and could create a massive short squeeze

Oncolytics submitted a Type D meeting request for REO 033, receiving feedback from the FDA and aligning on potential expansion and registrational path.

NeOnc’s (NASDAQ:NTHI) Phase 2a results for NEO100 in recurrent IDH1-mutant high-grade glioma make its Nasdaq Global Market listing way more interesting

Successfully transitioned SIL204 from regulatory preparation into an active Phase 2/3 clinical program in locally advanced pancreatic cancer, with trial initiation at Tel Aviv Sourasky Medical Center...

Enrollment ongoing in both QD and QW arms of global Phase I trial of pan-RAS(ON) inhibitor AN9025 First regulatory approval obtained for Phase I trial of pan-RAS(ON) ADC AN4035 Two leading...

NeOnc (NASDAQ: NTHI) delivered a brain cancer drug and non-invasive intranasal delivery double header breakthrough